9th Annual Biomarkers Congress

Approval of Additional Indications for the immunosuppressant Prograf® for Ulcerative Colitis in Japan

Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it was granted approval for moderately/severely refractory (steroid resistance and steroid dependency ) ulcerative colitis as additional indication for the immunosuppressant Prograf® (generic name: tacrolimus hydrate), submitted an sNDA to the Pharmaceuticals and Medical Devices Agency (PMDA) in June 2008 in Japan.

http://www.astellas.com/en/corporate/news/detail/approval-of-additional-indicat.html



Comments

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.